Talk:Ghrelin
From Wikipedia, the free encyclopedia
it is my understanding the levels of ghrelin present in the plasma of obese individuals is low ccompared to the amount present in lean individuals.
- Ghrelin levels in the plasma of obese individuals are lower than those in leaner individuals. Ghrelin levels low -> low stimulation of appetite -> individual eats less -> individual tends to be leaner than comparable group... I too must say it seems illogical that persons with low Ghrelin levels tend to be obese. --Abdull 15:52, 25 May 2006 (UTC)
--
"the novel stomach hormone ghrelin ... is an endogenous agonist at the growth hormone secretagogne [sic, s.b. secretagogue -dsws] receptor and is the motilin-related family of regulatory peptides" Abstract[1] full text[2]
dsws 20:02, 29 July 2005 (UTC) GHRELINWASORIGINALLY isolated from human and rat stomach as a cognate endogenous ligand for the GH secretagogue receptor. This 28-aminoacid peptide has a posttranslational n-octanoyl modification indispensable for its activity. Ghrelin stimulates GH release when peripherally or centrally administered to rats and when applied directly to rat primary pituitary cells. In addition, ghrelin administration increases food intake and body weight gain. Whereas ghrelin secretion is upregulated under negative energy balance conditions, including starvation, insulin-induced hypoglycemia, cachexia, and anorexia nervosa, it is down-regulated under conditions of positive energy balance, such as feeding, hyperglycemia, and obesity. Gastric ghrelin enters the brain across the blood-brain barrier . Recently, stomach-derived ghrelin’s signals for starvation has been reported to be relayed to the hindbrain via the vagus afferent nerve.Ateeq Muhammed Khaliq
Ghrelin, the endogenous ligand of the GH secretagogue receptor (GHS-R), is a newly identified, ubiquitously expressed molecule that has been involved in a wide array of endocrine and nonendocrine functions, including cell proliferation. In this context, the GHS-R type 1a, in the human ovary and testis as well as several testicular tumors. Ovarian malignancies, however, remain unexplored. Notably, a vast majority of ovarian tumors derive from the surface epithelium, which originates from the celomic epithelium. Considering the proven expression of ghrelin in the human ovary, and its reported effects in the proliferative activity of different cancer cell lines, we aimed at evaluating whether the ovarian surface epithelium as well as related reproductive structures and tumors are potential targets of ghrelin. To this end, expression of GHS-R1a was analyzed by immunohistochemistry in a panel of normal, metaplastic, and neoplastic tissues. Uniform GHS-R1a immunostaining was detected throughout the ovarian surface epithelium. Likewise, ciliated cells within the fallopian tube epithelium showed strong GHS-R1a expression. In contrast, other celomic derivatives, such as endometrium and endocervix, were negative for GHS-R1a immunoreactivity. In keeping with data from normal tissues, inclusion cysts from the surface epithelium expressed GHS-R1a. Similarly, benign serous tumors resembling fallopian tube epithelium were also positive, whereas serous cystadenocarcinomas showed GHS-R1a expression only in highly differentiated specimens. In contrast, other neoplasms, such as mucinous cystadenomas and cystadenocarcinomas, endometrioid tumors, clear cell carcinomas, and Brenner tumors, did not express GHS-R1a. In conclusion, our results demonstrate that the ovarian surface epithelium and related tumors are potential targets for systemic or locally produced ghrelin because they express the functional type 1a GHS-R. Considering the relevant role of the ovarian surface epithelium in key physiological events (such as ovulation) and neoplastic transformation of the ovary, the potential actions of ghrelin in those phenomena merit further investigation.--Ateeq 3:15, 23 of june 2006 (UTC) --
